CCN2 and hepatocellular carcinoma: Further, when we silenced endogenous CCN2 expression or treated HCC cell lines with a combination of sorafenib or U0126 and oxaliplatin, MAPK/Erk signaling was impaired and Id-1 expression was downregulated.